1-20 of 1389 Search Results for

drug

Follow your search
Access your saved searches in your account

Would you like to receive an alert when new items match your search?
×Close Modal
Sort by
Journal Article
Journal of Health Politics, Policy and Law (1 February 1979) 4 (1): 87–108.
Published: 01 February 1979
...James Christopher Anthony The Controlled Substances Act (CSA) is the prevailing “drug abuse” control statute in the United States. Its manifest objective is to prevent or reduce drug use's “substantial and detrimental effect on the health and general welfare of the American people.” Evaluating...
Journal Article
Journal of Health Politics, Policy and Law (1 June 2013) 38 (3): 545–571.
Published: 01 June 2013
... and efficacy information that the provinces use comes from the federal government. We interviewed drug plan officials from eight of the ten provinces and two of three territories regarding their views on the Canadian drug safety system. Here we report on the following categories: the federal drug...
Journal Article
Journal of Health Politics, Policy and Law (1 April 1998) 23 (2): 265–290.
Published: 01 April 1998
...Mae Thamer; Niall Brennan; Rafael Semansky Six countries—Canada, France, Japan, Sweden, the United Kingdom, and the United States—were studied to compare public policies affecting the development and marketing of pharmaceuticals for rare diseases (i.e., orphan drugs). Information was obtained from...
Journal Article
Journal of Health Politics, Policy and Law (1 April 1990) 15 (2): 357–385.
Published: 01 April 1990
...William E. McAuliffe As we enter the 1990s drug abuse has once again become a major health concern, and for the first time the drug treatment field has had to address many of the policy, regulation, and planning issues resulting from cost inflation that have become commonplace in other parts of...
Journal Article
Journal of Health Politics, Policy and Law (1 June 2004) 29 (3): 397–430.
Published: 01 June 2004
...Mary K. Olson This article examines the effects of the user fee reform on the speed of drug review in the U.S. Food and Drug Administration. The results show that even after controlling for increased agency resources, the reform reduced review times among new-drug approvals by 34 percent (95...
Journal Article
Journal of Health Politics, Policy and Law (1 June 2004) 29 (3): 431–442.
Published: 01 June 2004
...Daniel Carpenter © 2004 by Duke University Press 2004 Carpenter, Daniel P. 2000 . Protection without Capture: Drug Approval by a Politically Responsive, Bayesian Regulator . Robert Wood Johnson Foundation Scholars in Health Policy Working Paper No. 13. ———. 2002 . Groups, the Media, Agency...
Journal Article
Journal of Health Politics, Policy and Law (1 August 1989) 14 (4): 719–740.
Published: 01 August 1989
..., while similar programs have been instituted in other countries where intravenous drug use has also contributed to the spread of HIV infection and AIDS. Copyright © 1989 by Duke University Press 1989 References American Medical Association, Council on Scientific Affairs. 1988 . Reducing Transmission...
Journal Article
Journal of Health Politics, Policy and Law (1 August 1996) 21 (4): 751–768.
Published: 01 August 1996
... on the intended services or use budgetary strategies to appear to be in compliance with maintenance-of-effort provisions but then reallocate block grant funds from the targeted program. We studied the effect of the Alcohol, Drug Abuse, and Mental Health block grant program on state substance abuse...
Journal Article
Journal of Health Politics, Policy and Law (1 October 2010) 35 (5): 705–742.
Published: 01 October 2010
... outpatient prescription drugs is not. To solve problems of access, Canadian provinces have introduced provincial prescription drug benefit programs. This study analyzes the prescription drug policymaking process in five Canadian provinces between 1992 and 2004 with a view to (1) determining the federal...
Journal Article
Journal of Health Politics, Policy and Law (1 April 2007) 32 (2): 187–219.
Published: 01 April 2007
...Jonathan Oberlander The 2003 Medicare Prescription Drug, Improvement, and Modernization Act (MMA) represents a watershed event in Medicare politics. This essay explores the political lessons and policy legacies of the MMA, focusing on how the MMA fits with and deviates from established patterns in...
Journal Article
Journal of Health Politics, Policy and Law (1 April 2008) 33 (2): 225–247.
Published: 01 April 2008
...Joshua Parsons Cohen; Elly Stolk; Maartje Niezen There are three known criteria that underlie drug reimbursement decisions: therapeutic value, cost-effectiveness, and burden of disease. However, evidence from recent reimbursement decisions in several jurisdictions points to residual, unexplained...
Journal Article
Journal of Health Politics, Policy and Law (1 December 2008) 33 (6): 1079–1106.
Published: 01 December 2008
...Austin B. Frakt; Steven D. Pizer; Ann M. Hendricks Medicare and the Veterans Health Administration (VA) both finance large outpatient prescription drug programs, though in very different ways. In the ongoing debate on how to control Medicare spending, some suggest that Medicare should negotiate...
Journal Article
Journal of Health Politics, Policy and Law (1 April 2008) 33 (2): 319–324.
Published: 01 April 2008
...-health/2006-July/009888.html . DiMasi, J. A., R. W. Hansen, and H. G. Grabowski. 2003 . The Price of Innovation: New Estimates of Drug Development Costs. Journal of Health Economics 22 : 151 -185. ———. 2004 . Assessing Claims about the Cost of New Drug Development: A Critique of the Public...
Journal Article
Journal of Health Politics, Policy and Law (1 February 2003) 28 (1): 9–40.
Published: 01 February 2003
...Etienne E. Pracht; William J. Moore A simultaneous equations model is estimated to analyze the interaction between state Medicaid pharmaceutical drug reimbursement rates, drug recipients per capita, and expenditures per drug recipient. Interest groups are shown to have a strong positive impact on...
Journal Article
Journal of Health Politics, Policy and Law (1 October 2005) 30 (5): 978–985.
Published: 01 October 2005
...Harold Pollack; Soheil Soliman Robert J. MacCoun and Peter Reuter. Drug War Heresies: Learning from Other Vices, Times, and Places. Cambridge: Cambridge University Press, 2001. 479 pp. $29.95 paper. © 2005 by Duke University Press 2005 Books...
Journal Article
Journal of Health Politics, Policy and Law (1 April 1982) 7 (2): 521–523.
Published: 01 April 1982
...Peter Temin Milton Silverman, Philip R. Lee, and Mia Lydecker, Pills and the Public Purse: The Routes to National Drug Insurance (Berkeley: University of California Press, 1981), 232 pp., $15.95 hardbound Copyright © 1982 by the Department of Health Administration, Duke University Press 1982...
Journal Article
Journal of Health Politics, Policy and Law (1 April 1979) 4 (2): 155–175.
Published: 01 April 1979
...Michael Ira Smith; Albert I. Wertheimer In 1973 the federal government moved to limit drug reimbursement to providers in federally sponsored or supported programs, to the lowest cost at which the drug is generally and consistently available unless a difference in therapeutic effect can be...
Journal Article
Journal of Health Politics, Policy and Law (1 June 2013) 38 (3): 573–597.
Published: 01 June 2013
... also contribute to economic efficiency by creating transparency as the foundation of competitive generic drug markets, reducing transaction costs, and favoring trade. The law in most countries requires manufacturers to designate pharmaceuticals with INNs in labeling and advertising. Generic...
Journal Article
Journal of Health Politics, Policy and Law (1 December 2013) 38 (6): 1081–1102.
Published: 01 December 2013
... measurement of more meaningful clinical end points and increased engagement between manufacturers, drug regulators, and payers. A consistent finding in studies of reimbursement decisions is that economic considerations have been influential, second only to the strength of the clinical evidence for the drug of...
Journal Article
Journal of Health Politics, Policy and Law (1 August 2014) 39 (4): 751–780.
Published: 01 August 2014
...Thomas J. Hwang; Jerry Avorn; Aaron S. Kesselheim AbstractThe US Food and Drug Administration (FDA) uses rulemaking as one of its primary tools to protect the public health and implement laws enacted by Congress and the president. Because of the many effects that these rules have on social welfare...